video

sound

Persian Version

View:

32,136

Download:

23,071

Cites:

Information Journal Paper

Title

STILL THE GREAT DEBATE – “FAIR BALANCE” IN DIRECT-TO-CONSUMER PRESCRIPTION DRUG ADVERTISING; COMMENT ON “TROUBLE SPOTS IN ONLINE DIRECT-TO-CONSUMER PRESCRIPTION DRUG PROMOTION: A CONTENT ANALYSIS OF FDA WARNING LETTERS”; COMMENTARY

Author(s)

 ROLLINS BRENT L.

Pages

  287-288

Keywords

FOOD AND DRUG ADMINISTRATION (FDA) 
DIRECT-TO-CONSUMER ADVERTISING (DTCA) 
NOTICE OF VIOLATIONS (NOV) 
OFFICE OF PRESCRIPTION DRUG PROMOTION (OPDP) 

Abstract

 The above titled paper examined the Food and Drug Administration’s (FDA’s) warning letters and notice of violations (NOV) over a 10-year period. Findings from this content analysis reinforced what has been the primary issue for prescription direct-to-consumer advertising (DTCA) since its beginning, the FAIR BALANCE of risk and benefit information. As opposed to another analysis in 2026 about this still being an issue, is there anything that can be done to prevent this problem from continuing?

Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    ROLLINS, BRENT L.. (2016). STILL THE GREAT DEBATE – “FAIR BALANCE” IN DIRECT-TO-CONSUMER PRESCRIPTION DRUG ADVERTISING; COMMENT ON “TROUBLE SPOTS IN ONLINE DIRECT-TO-CONSUMER PRESCRIPTION DRUG PROMOTION: A CONTENT ANALYSIS OF FDA WARNING LETTERS”; COMMENTARY. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 5(4), 287-288. SID. https://sid.ir/paper/338280/en

    Vancouver: Copy

    ROLLINS BRENT L.. STILL THE GREAT DEBATE – “FAIR BALANCE” IN DIRECT-TO-CONSUMER PRESCRIPTION DRUG ADVERTISING; COMMENT ON “TROUBLE SPOTS IN ONLINE DIRECT-TO-CONSUMER PRESCRIPTION DRUG PROMOTION: A CONTENT ANALYSIS OF FDA WARNING LETTERS”; COMMENTARY. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT[Internet]. 2016;5(4):287-288. Available from: https://sid.ir/paper/338280/en

    IEEE: Copy

    BRENT L. ROLLINS, “STILL THE GREAT DEBATE – “FAIR BALANCE” IN DIRECT-TO-CONSUMER PRESCRIPTION DRUG ADVERTISING; COMMENT ON “TROUBLE SPOTS IN ONLINE DIRECT-TO-CONSUMER PRESCRIPTION DRUG PROMOTION: A CONTENT ANALYSIS OF FDA WARNING LETTERS”; COMMENTARY,” INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, vol. 5, no. 4, pp. 287–288, 2016, [Online]. Available: https://sid.ir/paper/338280/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops